Telomir Pharmaceuticals Overview
- Year Founded
-
2021
- Status
-
Public
- Employees
-
2
- Stock Symbol
-
TELO
- Investments
-
1
- Share Price
-
$0.35
- (As of Friday Closing)
Telomir Pharmaceuticals General Information
Description
Telomir Pharmaceuticals Inc is a preclinical-stage biotechnology company focused on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases rather than treating symptoms alone. The company's research targets fundamental cellular processes associated with disease progression and functional decline, including metal-ion dysregulation, oxidative stress, epigenetic regulation, mitochondrial dysfunction, and telomere integrity. Telomir's investigational compound, Telomir-1 (Zn-Telomir), is a novel orally administered small molecule engineered to modulate intracellular metal balance particularly iron, copper, calcium, and zinc.
Contact Information
Website
www.telomirpharma.comCorporate Office
- 100 South East 2nd Street
- Suite 2000 #1009
- Miami, FL 33131
- United States
Corporate Office
- 100 South East 2nd Street
- Suite 2000 #1009
- Miami, FL 33131
- United States
Telomir Pharmaceuticals Timeline
Telomir Pharmaceuticals Stock Performance
As of 20-Nov-2026, Telomir Pharmaceuticals’s stock price is $0.35. Its current market cap is $26.8M with 73.7M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.35 | $0.44 | $0.35 - $1.58 | $26.8M | 73.7M | 125K | -$0.96 |
Telomir Pharmaceuticals Financials Summary
As of 30-Sep-2026, Telomir Pharmaceuticals has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 77,360 | 38,397 | 121,746 | |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (5,686) | (10,539) | (12,242) | (11,429) |
| Net Income | (5,479) | (10,413) | (16,533) | (13,072) |
| Total Assets | 4,641 | 7,341 | 1,324 | 4,774 |
| Total Debt | 0 | 0 | 0 | 101 |
Telomir Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Telomir Pharmaceuticals Comparisons
Industry
Financing
Details
Telomir Pharmaceuticals Competitors (7)
One of Telomir Pharmaceuticals’s 7 competitors is Laminar Pharma, a Venture Capital-Backed company based in Palma de Mallorca, Spain.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Laminar Pharma | Venture Capital-Backed | Palma de Mallorca, Spain | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Celprogen | Private Debt Financed | Torrance, CA | ||||
| Stempeutics | Venture Capital-Backed | Bangalore, India | ||||
| Touchlight | Venture Capital-Backed | Hampton, United Kingdom |
Telomir Pharmaceuticals Patents
Telomir Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2022082079-A1 | Metalloenzyme inhibitors for treating cancers, alzheimer's disease, hemochromatosis, and other disorders | Inactive | 16-Oct-2020 |
Telomir Pharmaceuticals Signals
Telomir Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Telomir Pharmaceuticals Acquisitions (1)
Telomir Pharmaceuticals’s most recent deal was a Merger/Acquisition with TELI Pharmaceuticals for . The deal was made on 22-Apr-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| TELI Pharmaceuticals | 22-Apr-2026 | Merger/Acquisition | Pharmaceuticals |
Telomir Pharmaceuticals ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Telomir Pharmaceuticals FAQs
-
When was Telomir Pharmaceuticals founded?
Telomir Pharmaceuticals was founded in 2021.
-
Where is Telomir Pharmaceuticals headquartered?
Telomir Pharmaceuticals is headquartered in Miami, FL.
-
What is the size of Telomir Pharmaceuticals?
Telomir Pharmaceuticals has 2 total employees.
-
What industry is Telomir Pharmaceuticals in?
Telomir Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Telomir Pharmaceuticals a private or public company?
Telomir Pharmaceuticals is a Public company.
-
What is Telomir Pharmaceuticals’s stock symbol?
The ticker symbol for Telomir Pharmaceuticals is TELO.
-
What is the current stock price of Telomir Pharmaceuticals?
As of 20-Nov-2026 the stock price of Telomir Pharmaceuticals is $0.35.
-
What is the current market cap of Telomir Pharmaceuticals?
The current market capitalization of Telomir Pharmaceuticals is $26.8M.
-
Who are Telomir Pharmaceuticals’s competitors?
Laminar Pharma, Inovio Pharmaceuticals, Celprogen, Stempeutics, and Touchlight are some of the 7 competitors of Telomir Pharmaceuticals.
-
What is Telomir Pharmaceuticals’s annual earnings per share (EPS)?
Telomir Pharmaceuticals’s EPS for 12 months was -$0.96.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process